Mineralys Therapeutics (MLYS) Competitors

Mineralys Therapeutics (NASDAQ:MLYS) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.

Which has more risk and volatility, MLYS or CYTK?

Mineralys Therapeutics has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Does the media prefer MLYS or CYTK?

In the previous week, Cytokinetics had 10 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 27 mentions for Cytokinetics and 17 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.83 beat Cytokinetics' score of 0.75 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	13 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, MLYS or CYTK?

Mineralys Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$177.81M	-$3.73	-4.32
Cytokinetics	$19.22M	202.96	-$526.24M	-$5.29	-6.17

Is MLYS or CYTK more profitable?

Mineralys Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-67.97%	-62.40%
Cytokinetics	-17,906.25%	N/A	-50.21%

Do institutionals & insiders have more ownership in MLYS or CYTK?

84.5% of Mineralys Therapeutics shares are held by institutional investors. 25.6% of Mineralys Therapeutics shares are held by insiders. Comparatively, 2.7% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer MLYS or CYTK?

Mineralys Therapeutics currently has a consensus target price of $38.00, suggesting a potential upside of 136.02%. Cytokinetics has a consensus target price of $74.44, suggesting a potential upside of 127.92%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Mineralys Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Does the MarketBeat Community believe in MLYS or CYTK?

Cytokinetics received 809 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 95.24% of users gave Mineralys Therapeutics an outperform vote while only 79.94% of users gave Cytokinetics an outperform vote.

Company	Underperform	Outperform
Mineralys Therapeutics	Outperform Votes 20 95.24%	Underperform Votes 1 4.76%
Cytokinetics	Outperform Votes 829 79.94%	Underperform Votes 208 20.06%

Summary

Mineralys Therapeutics beats Cytokinetics on 10 of the 18 factors compared between the two stocks.